Real‐world safety and efficacy of apixaban versus standard thromboprophylaxis in newly diagnosed multiple myeloma: Insights from a multicentre retrospective cohort study

Guillaume Escure, Corinne Frere, Naella Lamamra, Benjamin Crichi, Laurent Frenzel, Salomon Manier, Emilie Chalayer

Open source

DOI
10.1111/bjh.70731
Published
2026-08-12
Container
British Journal of Haematology
Publisher
Wiley
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1111/bjh.70731,
  title = {Real‐world safety and efficacy of apixaban versus standard thromboprophylaxis in newly diagnosed multiple myeloma: Insights from a multicentre retrospective cohort study},
  author = {Guillaume Escure and Corinne Frere and Naella Lamamra and Benjamin Crichi and Laurent Frenzel and Salomon Manier and Emilie Chalayer},
  year = {2026},
  journal = {British Journal of Haematology},
  doi = {10.1111/bjh.70731},
  url = {https://doi.org/10.1111/bjh.70731}
}

RIS

TY  - JOUR
TI  - Real‐world safety and efficacy of apixaban versus standard thromboprophylaxis in newly diagnosed multiple myeloma: Insights from a multicentre retrospective cohort study
AU  - Guillaume Escure
AU  - Corinne Frere
AU  - Naella Lamamra
AU  - Benjamin Crichi
AU  - Laurent Frenzel
AU  - Salomon Manier
AU  - Emilie Chalayer
PY  - 2026
JO  - British Journal of Haematology
DO  - 10.1111/bjh.70731
UR  - https://doi.org/10.1111/bjh.70731
ER  - 

APA

Escure, G., Frere, C., Lamamra, N., Crichi, B., Frenzel, L., Manier, S., & Chalayer, E. (2026). Real‐world safety and efficacy of apixaban versus standard thromboprophylaxis in newly diagnosed multiple myeloma: Insights from a multicentre retrospective cohort study. British Journal of Haematology. https://doi.org/10.1111/bjh.70731

Source records